Navigation Links
Boehringer Ingelheim Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
Date:5/15/2013

tyrosine kinases shown to aid in the regulation of angiogenesis: fibroblast growth factor (FGF) receptor, platelet-derived growth factor (PDGF) receptor, and vascular endothelial growth factor (VEGF) receptor.

Nintedanib is being evaluated in various solid tumors – including advanced NSCLC, ovarian cancer, liver cancer (hepatic cell carcinoma), kidney cancer (renal cell carcinoma) and colorectal cancer. The advanced NSCLC and ovarian cancer clinical trials are in Phase III development. Nintedanib is also being investigated in Phase III trials for the treatment of Idiopathic Pulmonary Fibrosis (IPF), a progressive and severely debilitating lung disease.

Nintedanib is not approved by the FDA; its safety and efficacy have not been established. 

About Boehringer Ingelheim in Oncology

Building on scientific expertise and excellence in the fields of pulmonary and cardiovascular medicine, metabolic disease, neurology, virology and immunology, Boehringer Ingelheim has embarked on a major research program to discover and develop innovative cancer treatments.  Working in close collaboration with the international scientific community and a number of the world's leading cancer centers, Boehringer Ingelheim's commitment to oncology is underpinned by using advances in science to develop a range of targeted therapies for various solid tumors and hematological cancers. The current focus of late-stage research includes compounds in three areas: signal transduction inhibition, angiogenesis inhibition and cell-cycle kinase inhibition. The company is also evaluating a robust and growing pipeline of early-stage oncology compounds in areas including growth/survival signaling, immunotherapy and epigenetics.

For information about participating in a Boehringer Ingelheim clinical trial, please visit www.bicancertrials.com or call 1.866.725.7110. Healthcare providers interested in learning more
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
2. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
3. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
4. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
5. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
8. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
9. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
10. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
11. Boehringer Ingelheim Announces Equine Research Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)...  ACI Clinical ( www.aciclinical.com ) announces a ... Using this solution, trial sponsors can ... costs and receive the same expertise that has ... Leveraging a decade of DMC experience ... statistical programming and meeting facilitation), ACI analyzed DMC ...
(Date:8/21/2014)... Aug. 21, 2014  Armada Health Care (Armada), ... (GPO), is pleased to announce an agreement with ... host of innovative specialty pharmacy patient program offerings. ... therapy management services to specialty patients via Armada,s ... Aurora will use the OTM platform as ...
(Date:8/21/2014)... 21, 2014  The board of directors of VirtualScopics, ... of clinical trial imaging solutions, today announced that ... officer, effective immediately.  Mr. Groff has held the role ... joined VirtualScopics in January 2006 as an accounting manager ... "When the board of VirtualScopics asked Jim to ...
Breaking Medicine Technology:ACI Clinical: Innovation and Savings in Data Safety Monitoring Committees 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 3VirtualScopics, Inc. Names James Groff Chief Financial Officer 2VirtualScopics, Inc. Names James Groff Chief Financial Officer 3VirtualScopics, Inc. Names James Groff Chief Financial Officer 4
... ATHX ) today announced that its CEO, Dr. ... DATE: , January 11, 2011TIME: , 10:00 AM ... online event where investors are invited to ask the company ... as the company,s "virtual trade booth." If attendees are not ...
... British Columbia, Jan. 7, 2011 Enox Biopharma, Inc. CEO, ... OneMedForum Emerging Company Finance Conference on Wednesday, January 12 at ... Sir Francis Drake Hotel in San Francisco. ... its ability to embed nitric oxide into polymer based medical ...
Cached Medicine Technology:Athersys to Present Live at Retail Investor Conferences.com on January 11th 2Enox Biopharma, Inc. to Present at OneMedForum Emerging Company Finance Conference. 2
(Date:8/21/2014)... finding motivation to exercise is a challenge. Thankfully, there are ... Zombies, Run!one of more than 31,000 health and fitness apps ... of apps that use games to increase physical activity. , ... makers looking to cash in to help people get fit. ... to be seen. , "It,s just been assumed that gamified ...
(Date:8/21/2014)... August 21, 2014 Improv performers from ... residents with dementia at Silverado Turtle Creek memory care ... consists of entertainers ranging from ages 10 to 16, ... perform their 40-minute set. The troupe's philosophy is that ... and allows them to touch audiences regardless of their ...
(Date:8/21/2014)... American women born at a low or very low ... developing type 2 diabetes. The findings, which appear in ... higher occurrence of type 2 diabetes in African American ... weight. , Researchers from Boston University,s Slone Epidemiology Center ... Women,s Health Study over the course of 16 years, ...
(Date:8/21/2014)... is eating better and exercising healthy for people with diabetes, ... a new study finds. The study, led by Mark ... Baptist Medical Center in Winston-Salem, N.C., included more than ... Participants ranged in age from 45 to 76, and ... focused on diet and exercise, or to a standard diabetes ...
(Date:8/21/2014)... HealthDay Reporter THURSDAY, ... therapy and antidepressants appears to best help people with ... Four out of five people suffering from severe depression ... treated with cognitive therapy plus antidepressant medication, researchers found. ... much better than drugs alone in helping people with ...
Breaking Medicine News(10 mins):Health News:Playing hunger games: Are gamified health apps putting odds in your favor? 2Health News:Unicorn Clearance Improv Troupe Brings Laughter to Residents with Dementia at Silverado Memory Care 2Health News:Low birth weight linked to higher incidence of type 2 diabetes in African American women 2Health News:Getting Healthier a Big Money-Saver for People With Diabetes 2Health News:Talk Therapy Plus Meds May Be Best for Severe Depression 2Health News:Talk Therapy Plus Meds May Be Best for Severe Depression 3
... predisposed to giving birth prematurely, according to a new ... is an important first step toward identifying women at ... lead to treatments. ,Researchers at the university ... kept by the Missouri Department of Health and Senior ...
... Socrates is smiling. His move to lift a ban on abortion ... in favor of the ban being lifted or, legalizing abortion. ... catholic nations that prohibit abortion or destruction of unborn children, due ... up to 3 years prison term and those who aid them ...
... to have struck the honeybee population across the country killing ... affected by this weird ailment. This has adversely affected the ... have reported a loss of at least half of their ... devastated many beehives and their populations in US. Though such ...
... on Thursday expressed confidence in their efforts to reduce the ... bird flu, after two separate incidents at poultry farms in ... over [for bird flu], but we have sufficient monitoring and ... sporadic cases that might occur," Muhammad Afzal, a spokesman for ...
... Davis have created a new type of nanoparticle that ... contamination of food products, as well as for medical ... of the journal Nanotechnology. ,Nanoparticles, according to ... aeronautical engineering and senior author of a paper describing ...
... for diabetes has been recognized resulting in tests that could ... journal Nature. ,Professor Philippe Froguel of Imperial ... said that hereditary and life style patterns are linked to ... at a genetic test that would envisage people who would ...
Cached Medicine News:Health News:Genes May Trigger Repeated Premature Birth In Blacks 2Health News:Pakistan: Authorities Plays Down Bird Flu Risk 2Health News:UC Davis Creates New Nanoparticles 2
... Immune Complexes from patient serum or plasma, standards ... onto microtiter wells. After a washing step, ... binds to the Fc region of human IgG. ... is pipetted followed by a stopping step. ...
...
...
...
Medicine Products: